Melatonina

Gender-related invasion differences associated with mRNA expression levels of melatonin membrane receptors in colorectal cancer

Mol Carcinog. 2012 Aug;51(8):608-18.
León J, Casado J, Carazo A, Sanjuán L, Maté A, Muñoz de Rueda P, de la Cueva P, Quiles R, Ruíz S, Ruíz-Extremera A, Salmerón J.
Melatonin inhibits growth and invasive capacity of colon cancer cells in vitro through its membrane (MT1 and MT2) and/or nuclear receptors (RORα).
MT1- MT2 - RORα

Neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin as a second-line treatment in metastatic colorectal carcinoma

Tumori. 1992 Dec 31;78(6):383-7.
Barni S, Lissoni P, Cazzaniga M, Ardizzoia A, Paolorossi F, Brivio F, Perego M, Tancini G, Conti A, Maestroni G.
Neuroimmunotherapy with low-dose interleukin-2 and MLT(50mg/day orally), does not seem to be effective in terms of tumor regression in metastatic colon cancer patients pretreated with 5-fluorouracil.
Interleukin 2 (IL-2) plus MLT.

Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: preliminary results

Eur J Cancer. 1993;29A(2):185-9.
Lissoni P, Barni S, Rovelli F, Brivio F, Ardizzoia A, Tancini G, Conti A, Maestroni GJ.
Neuroimmunotherapy with low-dose IL-2 and MLT (50mg/day orally) is a biologically active and well tolerated strategy, capable of determining an apparent control of tumour growth in patients with advanced solid neoplasms.
Interleukin 2 (IL-2) plus .MLT

Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract

Br J Cancer.1993 Jun;67(6):1404-7.
Lissoni P, Barni S,Tancini G, Ardizzoia A, Rovelli F, Cazzaniga M, Brivio F, Piperno A, Aldeghi R, Fossati D, et al.
The immunotherapy with low-dose IL-2 plus MLT (50mg/day orally) is a new well tolerated and effective therapy of advanced tumours of digestive tract.
Interleukin 2 (IL-2) plus MLT.

A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma

Br J Cancer. 1994 Jan;69(1):196-9.
Lissoni P, Barni S, Tancini G, Ardizzoia A, Ricci G, Aldeghi R, Brivio F, Tisi E, Rovelli F, Rescaldani R, et al.
The concomitant administration of MLT (40 mg day orally) may increase the efficacy of low-dose IL-2 subcutaneous therapy.Tumour objective regression rate was 11/41 vs 1/39, P < 0.001.
Interleukin 2 (IL-2) plus MLT.

Pagine

Abbonamento a RSS - Melatonina